More than 1 in 8 women who undergo mastectomy with reconstruction for breast cancer treatment or prophylaxis become persistent users of controlled substances, according to a retrospective cohort study.
Women who receive mastectomy and reconstructive surgery as part of breast cancer treatment may face the risk of developing persistent use of opioids and sedative-hypnotic drugs, according to data presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.